IRVING, Texas, April 7, 2011 (GLOBE NEWSWIRE) -- Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, this weekend presented significant findings regarding the potential role of circulating microvesicles (cMV) as a non-invasive blood-based testing technology at the American Association for Cancer Research (AACR) annual meeting. The data presented supports the potential of cMV in the development of various blood-based diagnostic, prognostic and theranostic tests, as well as for therapeutic response measurement. Being developed by Caris Life Sciences, under the trade name Carisome™, this versatile blood-based technology is being studied for potential utility as an aid in the diagnosis of common cancers such as colon, breast, lung and prostate cancer, as well as other complex diseases.
